Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Elan to Pay Shareholders Tysabri Dividends in Challenge to Bid

March 4 (Bloomberg) -- Elan Corp. said it will pay shareholders dividends from its royalties from multiple-sclerosis drug Tysabri in a challenge to a $6.5 billion bid from RP Management LLC for the Dublin-based drugmaker.

Biogen Idec Inc. on Feb. 6 agreed to buy Elan’s stake in the Tysabri drug for $3.25 billion in cash plus future royalties. The drug generated $1.6 billion in sales in 2012. Elan said today it will pay shareholders dividends directly linked to Tysabri’s market performance as a 20 percent share of the royalty received from Biogen Idec.

RP Management offered to buy Elan on Feb. 25, saying a sale would allow shareholders to avoid the substantial risks of Chief Executive Officer Kelly Martin’s plan to make purchases with the proceeds from Tysabri.

Martin said today that together with a $1 billion share-repurchase program announced Feb. 22 and plans to buy additional drug assets, the dividend provides shareholders “significant near- and longer-term benefits.”

To contact the reporter on this story: Kim McLaughlin in Stockholm at kmclaughlin6@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.